Disc Medicine (IRON) CEO On Treating Patients With Hematologic Diseases

Disc Medicine (IRON) is a biopharmaceutical company that treats patients with hematologic diseases. IRON is to report its 2Q23 earnings on Monday, August 14th. Its EPS is estimated at -$0.88. IRON's 52-week high came in at $57.7, while its low came in at $11.80. IRON is up over 120% year-to-date and up 150% year-over-year. President and CEO of IRON, John Quisel, gives and overview of the company and previews its earnings. He also talks about how the company helps patients. Tune in to find out more about the stock market today.